Drug reference

apomorphine

Nonergot alkaloid, Pan-DA Receptor Agonist · Parkinson's disease treatment

Nonergot alkaloid, Pan-DA Receptor AgonistParkinson's disease treatment

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

incl. contraindicated

PREGNANCY

—

not curated

Top interactionssee all 12 →

OndansetronContraindicatedDatabaseKimi deep-research + Cla
AlosetronSevereDatabaseDDInter
AmiodaroneSevereDatabaseDDInter
AmisulprideSevereDatabaseDDInter

Mechanism

Not yet extracted

Indications

Acute treatment of sudden "off" periods (bradykinesia, freezing) in Parkinson's diseaseAcute intermittent treatment of off episodes in patients with a fluctuating response to dopaminergic therapy (rescue therapy)inducing vomiting (in cases of ingested poison)

Dosing

Adult: 6 mg, i.m./s.c.

Contraindications

if respiration is depressed

Side effects

Common

highly emetogenic (nausea/vomiting)injection site reactionsoral sores and/or pain (sublingual formulation)

Serious

profound hypotension
loss of consciousness
QT prolongation
development of a pattern of abuse characterized by increasingly frequent dosing leading to hallucinations, dyskinesia, and abnormal behavior
respiratory depression
CNS depression

Drug interactions

Ondansetron

Contraindicated

Database

Concomitant use of ondansetron with apomorphine causes profound hypotension (systolic BP drop >20-30 mmHg) and loss of consciousness in most patients. The mechanism involves additive effects on dopaminergic and serotonergic pathways in the cardiovascular regulatory centers.

CONTRAINDICATED. Do not coadminister under any circumstances. If antiemetic therapy is needed in a patient on apomorphine, consider prochlorperazine, metoclopramide, or trimethobenzamide as alternatives.

Source: Kimi deep-research + Cla

Alosetron

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amiodarone

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amisulpride